2371-29-1 Usage
Uses
Used in Pharmaceutical Research:
(2-Chloro-phenylamino)-acetic acid hydrazide is used as a chemical intermediate for the development of new pharmaceutical agents, particularly in the synthesis of heterocyclic compounds. Its unique structure and reactivity make it a valuable component in the creation of novel drug molecules with potential therapeutic benefits.
Used in Antituberculosis Applications:
In experimental studies, (2-Chloro-phenylamino)-acetic acid hydrazide has demonstrated potential as an antituberculosis agent. It is used for its ability to target and inhibit the growth of Mycobacterium tuberculosis, the causative agent of tuberculosis, offering a new avenue for the development of more effective treatments against this persistent and challenging disease.
Used in Antimicrobial Applications:
(2-Chloro-phenylamino)-acetic acid hydrazide is also used as an antimicrobial agent, showing promise in combating various types of bacteria. Its broad-spectrum activity and potential to disrupt bacterial growth mechanisms make it a valuable asset in the ongoing battle against antibiotic-resistant infections.
Used in Chemical Research:
As a hydrazine derivative, (2-Chloro-phenylamino)-acetic acid hydrazide is used in chemical research to explore its reactivity, stability, and potential applications in the synthesis of various organic and inorganic compounds. Its unique properties and versatility contribute to the advancement of chemical science and the development of new materials and technologies.
Check Digit Verification of cas no
The CAS Registry Mumber 2371-29-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,3,7 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 2371-29:
(6*2)+(5*3)+(4*7)+(3*1)+(2*2)+(1*9)=71
71 % 10 = 1
So 2371-29-1 is a valid CAS Registry Number.
InChI:InChI=1/C8H10ClN3O/c9-6-3-1-2-4-7(6)11-5-8(13)12-10/h1-4,11H,5,10H2,(H,12,13)
2371-29-1Relevant academic research and scientific papers
Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
Okawa, Tomohiro,Aramaki, Yoshio,Yamamoto, Mitsuo,Kobayashi, Toshitake,Fukumoto, Shoji,Toyoda, Yukio,Henta, Tsutomu,Hata, Akito,Ikeda, Shota,Kaneko, Manami,Hoffman, Isaac D.,Sang, Bi-Ching,Zou, Hua,Kawamoto, Tetsuji
, p. 6942 - 6990 (2017/09/07)
A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.
